7:05 am Verastem acquires rights to cancer stem cell inhibitor VS-4718; acquisition reduces milestones and royalties associated with ongoing VS-4718 development

more

View todays social media effects on VSTM

View the latest stocks trending across Twitter. Click to view dashboard

See who Verastem is hiring next, click here to view